The MarketReader Minute
💊 Biotech Slips Despite Breakthroughs; Exelixis Jumps, Gilead Falls to 4-Week Low | Biotech Sector Insights
The biotech sector edged lower despite upbeat sentiment following a reported Type 1 diabetes breakthrough from Vertex. IBB was weighed down by weakness in Gilead, Biogen, and Sarepta, the latter facing continued fallout from its halted gene therapy trial.